News from exact sciences corp A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 10, 2019, 06:00 ET Cologuard® Helps More People Get Screened In A Cost-Effective Way

(NASDAQ: EXAS) -- Exact Sciences announced today that nearly 3 million people have been screened for colorectal cancer with Cologuard since FDA...


Aug 30, 2019, 09:15 ET Exact Sciences to participate in September investor conference

Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conference and invited...


Aug 02, 2019, 06:00 ET Exact Sciences to participate in August investor conference

Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conference and invited...


Jul 17, 2019, 06:00 ET Exact Sciences Designated a Great Place to Work-Certified™ Company in 2019

The more than 2,400 people of Exact Sciences work every day to create life-changing innovations in earlier cancer detection. In the process, they...


Jul 09, 2019, 06:00 ET Exact Sciences to host annual meeting, second-quarter 2019 results webcasts and calls

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host webcasts and conference calls of its annual stockholders meeting and...


Jun 26, 2019, 16:05 ET Exact Sciences Advances Fight Against Colorectal Cancer With Opening Of New Laboratory

Less than 20 months after breaking ground, Exact Sciences today opened the doors on its new, 169,000 square foot clinical laboratory and warehouse on ...


May 31, 2019, 06:00 ET Exact Sciences to participate in June investor conferences

Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conferences and invited...


May 20, 2019, 08:56 ET Exact Sciences Advances Pipeline Capabilities with Mayo Clinic

Early research using blood-based methylated DNA markers, identified through the longstanding collaboration between Exact Sciences and Mayo Clinic,...


May 17, 2019, 05:30 ET Exact Sciences Presents New Data Reinforcing Performance of Cologuard®

New research from Exact Sciences and Mayo Clinic demonstrates the ability of Cologuard to both screen large patient populations and consistently help ...


May 01, 2019, 06:00 ET Exact Sciences to participate in May investor conferences

Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conferences and invited...


Apr 30, 2019, 16:05 ET First-quarter revenue and Cologuard test volume increased 79 percent to $162 million and 334,000, respectively

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $162.0 million and screened approximately 334,000 people...


Apr 08, 2019, 06:00 ET Exact Sciences schedules first-quarter 2019 earnings call

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its first-quarter 2019 financial results after the close of the ...


Mar 19, 2019, 08:00 ET Kathleen Sebelius Appointed to Exact Sciences Board

Kathleen Sebelius, the 21st Secretary of the U.S. Department of Health and Human Services (HHS) from April 2009 to June 2014 and governor of Kansas...


Mar 06, 2019, 00:14 ET Exact Sciences Announces Upsizing and Pricing of 0.3750% Convertible Senior Notes Due 2027

Exact Sciences Corporation (NASDAQ: EXAS) announced today that it has priced its underwritten public offering of 0.3750% convertible senior notes due ...


Mar 05, 2019, 16:01 ET Exact Sciences Announces Offering of $600 Million Convertible Senior Notes Due 2027

Exact Sciences Corporation (NASDAQ: EXAS) (the "Company") today announced an underwritten public offering of $600 million aggregate principal amount...


Mar 01, 2019, 06:00 ET Exact Sciences to participate in March investor conferences

Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conferences and invited...


Feb 27, 2019, 06:00 ET Cologuard Helps Screen Two Million People for Colorectal Cancer

In less than five years, more than two million Americans have screened for colorectal cancer with Cologuard. Exact Sciences Corp., which created the...


Feb 21, 2019, 16:05 ET Total 2018 revenue increased 71 percent to $454 million, and 934,000 people were screened with Cologuard

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $454.5 million and completed approximately 934,000...


Feb 21, 2019, 08:02 ET 2019 Cologuard Classic Ups the Ante with New 'Hole-In-One Attendance Challenge' to Drive Awareness of Colorectal Cancer and Importance of Early Detection

Exact Sciences, the makers of Cologuard – a noninvasive colorectal cancer screening test, is upping the ante at the 2019 Cologuard Classic PGA TOUR...


Feb 04, 2019, 06:00 ET Exact Sciences schedules fourth-quarter, full-year 2018 earnings call

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its fourth-quarter and full-year 2018 financial results after...


Jan 06, 2019, 19:00 ET Exact Sciences to report $454-455M in total revenue, 71-percent growth for 2018

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company expects to report revenue between $142.5 million and $143.5 million for the...


Dec 20, 2018, 06:00 ET Exact Sciences to participate in J.P. Morgan Healthcare Conference

Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conference and invited...


Nov 09, 2018, 06:00 ET Exact Sciences to participate in two November investor conferences

Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conference during November...


Oct 30, 2018, 16:05 ET Cologuard® revenue increased 63 percent to $118 million, and Cologuard test volume grew 49 percent to 241,000 during third quarter

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $118.3 million and screened approximately 241,000 people...


Oct 18, 2018, 07:00 ET Exact Sciences Strengthens Pipeline Capabilities with Acquisition of Biomatrica, a Leading Provider of Biological Sample Preservation Technology

Exact Sciences Corp. (Nasdaq: EXAS) today announced the acquisition of Biomatrica, a leading developer, manufacturer and provider of sample...